BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Nagel DJ, Rackow AR, Ku W, Bell TJ, Sime PJ, Kottmann RM. Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation and Fibrosis; Potential Implications for Idiopathic Pulmonary Fibrosis. Cells 2022;11:2540. [DOI: 10.3390/cells11162540] [Reference Citation Analysis]
2 Zi D, Li Q, Xu CX, Zhou ZW, Song GB, Hu CB, Wen F, Yang HL, Nie L, Zhao X, Tan J, Zhou SF, He ZX. CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma. Aging (Albany NY) 2022;14:4673-98. [PMID: 35681259 DOI: 10.18632/aging.203241] [Reference Citation Analysis]
3 Suteau V, Seegers V, Munier M, Ben Boubaker R, Reyes C, Gentien D, Wery M, Croué A, Illouz F, Hamy A, Rodien P, Briet C. G Protein-coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine. J Clin Endocrinol Metab 2021;106:2221-32. [PMID: 34000025 DOI: 10.1210/clinem/dgab343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Gonçalves-Monteiro S, Ribeiro-Oliveira R, Vieira-Rocha MS, Vojtek M, Sousa JB, Diniz C. Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases. Pharmaceuticals (Basel) 2021;14:439. [PMID: 34066915 DOI: 10.3390/ph14050439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Wang J, Xu M, Li DD, Abudukelimu W, Zhou XH. GPR37 promotes the malignancy of lung adenocarcinoma via TGF-β/Smad pathway. Open Med (Wars) 2021;16:24-32. [PMID: 33364431 DOI: 10.1515/med-2021-0011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Harvey BJ. Guest editorial: 11th international meeting on rapid responses to steroid hormones RRSH2018. Steroids 2020;154:108552. [PMID: 31816360 DOI: 10.1016/j.steroids.2019.108552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nagel DJ, Clough R, Bell TJ, Ku W, Sime PJ, Kottmann RM. The Role of the Ovarian Cancer G -Coupled Receptor (OGR1) in Idiopathic Pulmonary Fibrosis.. [DOI: 10.1101/849117] [Reference Citation Analysis]
8 Puchert M, Obst J, Koch C, Zieger K, Engele J. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7. Cytokine 2020;125:154809. [PMID: 31437604 DOI: 10.1016/j.cyto.2019.154809] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
9 Mero M, Asraf H, Sekler I, Taylor KM, Hershfinkel M. ZnR/GPR39 upregulation of K+/Cl--cotransporter 3 in tamoxifen resistant breast cancer cells. Cell Calcium 2019;81:12-20. [PMID: 31146164 DOI: 10.1016/j.ceca.2019.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
10 Lappano R, Jacquot Y, Maggiolini M. GPCR Modulation in Breast Cancer. Int J Mol Sci 2018;19:E3840. [PMID: 30513833 DOI: 10.3390/ijms19123840] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
11 Slater K, Hoo PS, Buckley AM, Piulats JM, Villanueva A, Portela A, Kennedy BN. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer Metastasis Rev 2018;37:335-45. [DOI: 10.1007/s10555-018-9751-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
12 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
13 Kübler E, Albrecht H. Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines. Oncotarget 2018;9:24882-97. [PMID: 29861840 DOI: 10.18632/oncotarget.25427] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
14 De Francesco EM, Sotgia F, Clarke RB, Lisanti MP, Maggiolini M. G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. Int J Mol Sci 2017;18:E2713. [PMID: 29240722 DOI: 10.3390/ijms18122713] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
15 Fehrenbacher N, Philips MR. Targeting RAS - will GPR31 deliver us a new path forward? Mol Cell Oncol 2017;4:e1359228. [PMID: 29209647 DOI: 10.1080/23723556.2017.1359228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Tian J, Wang Y, Zhang X, Ren Q, Li R, Huang Y, Lu H, Chen J. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling. J Exp Clin Cancer Res 2017;36:153. [PMID: 29096683 DOI: 10.1186/s13046-017-0625-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]